Penicillin-probenecid therapy is generally limited to those infections where very high serum levels of penicillin are necessary. Probenecid decreases the apparent volume of distribution and slows the rate of excretion by competitively inhibiting renal tubular secretion of penicillin. Treatment of endocarditis and osteomyelitis may require a longer duration of therapy.Ĭoncurrent administration of Bristopen (Bristopen (Bristopen for injection) for injection) and probenecid increases and prolongs serum penicillin levels. Therapy should be continued for at least 48 hours after the patient has become afebrile, asymptomatic, and cultures are negative. In severe staphylococcal infections, therapy with Bristopen (Bristopen (Bristopen for injection) for injection) should be continued for at least 14 days. Duration of therapy varies with the type of severity of infection as well as the overall condition of the patient therefore, it should be determined by the clinical and bacteriological response of the patient. Other dosage forms may be more appropriate.īacteriologic studies to determine the causative organisms and their susceptibility to Bristopen (Bristopen (Bristopen for injection) for injection) should always be performed. This container system may be inappropriate for the dosage requirements for children, infants and neonates. every 4-6 hours (mild to moderate infections) The usual dose recommendation is as follows: In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.īristopen (Bristopen (Bristopen for injection) for injection) Injection, USP supplied as a premixed frozen solution is to be administered as a continuous or intermittent intravenous infusion. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bristopen Injection, USP and other antibacterial drugs, Bristopen (Bristopen (Bristopen for injection) for injection) Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. If the susceptibility tests indicate that the infection is due to an organism other than a resistant Staphylococcus, therapy should not be continued with Bristopen (Bristopen (Bristopen for injection) for injection). Bristopen (Bristopen (Bristopen for injection) for injection) should not be used in infections caused by organisms susceptible to penicillin G. (See CLINICAL PHARMACOLOGY - Susceptibility Tests).īristopen (Bristopen (Bristopen for injection) for injection) may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results.

Cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug. It does not store any personal data.Bristopen (Bristopen (Bristopen for injection) for injection) is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. The cookie is used to store the user consent for the cookies in the category 'Performance'. This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category 'Other. The cookies is used to store the user consent for the cookies in the category 'Necessary'. The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category 'Functional'. The cookie is used to store the user consent for the cookies in the category 'Analytics'. These cookies ensure basic functionalities and security features of the website, anonymously.

Necessary cookies are absolutely essential for the website to function properly.

Briqs open